These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 35708313)

  • 1. Antibody response to SARS-CoV-2 vaccines among hospitalized patients in China: a case-control study.
    Li FP; Shi GF; Lin ZZ; Zhu XL; Wang LJ; Tung TH; Zhang MX
    Hum Vaccin Immunother; 2022 Nov; 18(5):2088966. PubMed ID: 35708313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Factors Affecting Side Effects, Seroconversion Rates and Antibody Response After Inactivated SARS-CoV-2 Vaccination in Healthcare Workers].
    Şenol Akar Ş; Akçalı S; Özkaya Y; Gezginci FM; Cengiz Özyurt B; Deniz G; Karadağ Yalçın F; Özer D; Dündar Erbay P; Eser E
    Mikrobiyol Bul; 2021 Oct; 55(4):519-538. PubMed ID: 34666653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Higher antibody responses after mRNA-based vaccine compared to inactivated vaccine against SARS-CoV-2 in Behcet's syndrome.
    Ozdede A; Nohut OK; Atli Z; Tok YT; Guner S; Yilmaz E; Ucar D; Uygunoglu U; Hamuryudan V; Seyahi E
    Rheumatol Int; 2022 Oct; 42(10):1741-1750. PubMed ID: 35779083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody response with SARS-CoV-2 inactivated vaccine (CoronaVac) in Turkish geriatric population.
    Okyar Baş A; Hafizoğlu M; Akbiyik F; Güner Oytun M; Şahiner Z; Ceylan S; Ünsal P; Doğu BB; Cankurtaran M; Çakir B; Ünal S; Halil MG
    Age Ageing; 2022 May; 51(5):. PubMed ID: 35524745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Humoral Immune Response in Inactivated SARS-CoV-2 Vaccine: When Should a Booster Dose be Administered?].
    Kara E; Tanır F; Demirhindi H; Mete B; Kibar F; Çetiner S; Candevir A; İnaltekin A
    Mikrobiyol Bul; 2022 Jul; 56(3):566-573. PubMed ID: 35960246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impaired antibody response to inactivated COVID-19 vaccines in hospitalized patients with type 2 diabetes.
    Zhou X; Lu H; Sang M; Qiu S; Yuan Y; Wu T; Chen J; Sun Z
    Hum Vaccin Immunother; 2023 Dec; 19(1):2184754. PubMed ID: 36864628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV: A structured summary of a study protocol for a randomised controlled trial.
    Palacios R; Patiño EG; de Oliveira Piorelli R; Conde MTRP; Batista AP; Zeng G; Xin Q; Kallas EG; Flores J; Ockenhouse CF; Gast C
    Trials; 2020 Oct; 21(1):853. PubMed ID: 33059771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore.
    Ng OT; Marimuthu K; Lim N; Lim ZQ; Thevasagayam NM; Koh V; Chiew CJ; Ma S; Koh M; Low PY; Tan SB; Ho J; Maurer-Stroh S; Lee VJM; Leo YS; Tan KB; Cook AR; Tan CC
    JAMA Netw Open; 2022 Aug; 5(8):e2228900. PubMed ID: 36018588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
    Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
    Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human IgM and IgG Responses to an Inactivated SARS-CoV-2 Vaccine.
    Banga Ndzouboukou JL; Zhang YD; Lei Q; Lin XS; Yao ZJ; Fu H; Yuan LY; Fan XL
    Curr Med Sci; 2021 Dec; 41(6):1081-1086. PubMed ID: 34741251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody Response to SARS-CoV-2 Vaccines in People with Severe Obesity.
    Kara Z; Akçin R; Demir AN; Dinç HÖ; Taşkın HE; Kocazeybek B; Yumuk VD
    Obes Surg; 2022 Sep; 32(9):2987-2993. PubMed ID: 35802279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study.
    Barin B; Kasap U; Selçuk F; Volkan E; Uluçkan Ö
    Lancet Microbe; 2022 Apr; 3(4):e274-e283. PubMed ID: 35165669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody response to two doses of inactivated SARS-CoV-2 vaccine (CoronaVac) in kidney transplant recipients.
    Eren Sadioğlu R; Demir E; Evren E; Aktar M; Şafak S; Artan AS; Meşe S; Ağaçfidan A; Çınar G; Önel M; Karahan ZC; Şengül Ş; Keven K; Türkmen A
    Transpl Infect Dis; 2021 Dec; 23(6):e13740. PubMed ID: 34606134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and immune-persistence of the CoronaVac or Covilo inactivated COVID-19 Vaccine: a 6-month population-based cohort study.
    Hua Q; Zhang H; Yao P; Xu N; Sun Y; Lu H; Xu F; Liao Y; Yang J; Mao H; Zhang Y; Zhu H; Hu X; Lv H; Jiang J
    Front Immunol; 2022; 13():939311. PubMed ID: 36032136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody response after a third dose mRNA-1273 vaccine among vaccinated healthcare workers with two doses of inactivated SARS-CoV-2 vaccine.
    Cucunawangsih C; Wijaya RS; Lugito NPH; Suriapranata I
    Int J Infect Dis; 2022 May; 118():116-118. PubMed ID: 35192955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
    Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
    Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study.
    Aikawa NE; Kupa LVK; Pasoto SG; Medeiros-Ribeiro AC; Yuki EFN; Saad CGS; Pedrosa T; Fuller R; Shinjo SK; Sampaio-Barros PD; Andrade DCO; Pereira RMR; Seguro LPC; Valim JML; Waridel F; Sartori AMC; Duarte AJS; Antonangelo L; Sabino EC; Menezes PR; Kallas EG; Silva CA; Bonfa E
    Lancet Rheumatol; 2022 Feb; 4(2):e113-e124. PubMed ID: 34901885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of antibody response after two doses of the Sinovac vaccine and the potential need for booster doses in cancer patients.
    Ata S; Cil T; Duman BB; Unal N
    J Med Virol; 2022 Jun; 94(6):2487-2492. PubMed ID: 35181932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial.
    Madhi SA; Koen AL; Izu A; Fairlie L; Cutland CL; Baillie V; Padayachee SD; Dheda K; Barnabas SL; Bhorat QE; Briner C; Aley PK; Bhikha S; Hermanus T; Horne E; Jose A; Kgagudi P; Lambe T; Masenya M; Masilela M; Mkhize N; Moultrie A; Mukendi CK; Moyo-Gwete T; Nana AJ; Nzimande A; Patel F; Rhead S; Taoushanis C; Thombrayil A; van Eck S; Voysey M; Villafana TL; Vekemans J; Gilbert SC; Pollard AJ; Moore PL; Kwatra G;
    Lancet HIV; 2021 Sep; 8(9):e568-e580. PubMed ID: 34416193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.